vs
Side-by-side financial comparison of Blue Foundry Bancorp (BLFY) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.
Blue Foundry Bancorp is the larger business by last-quarter revenue ($13.3M vs $13.2M, roughly 1.0× TriSalus Life Sciences, Inc.). Blue Foundry Bancorp runs the higher net margin — -27.4% vs -73.9%, a 46.5% gap on every dollar of revenue. On growth, TriSalus Life Sciences, Inc. posted the faster year-over-year revenue change (59.8% vs 34.2%). Over the past eight quarters, TriSalus Life Sciences, Inc.'s revenue compounded faster (43.0% CAGR vs 16.0%).
Blue Foundry Bancorp is a regional bank holding company based in New Jersey, United States. It offers a comprehensive range of personal and commercial banking products, including deposit accounts, consumer loans, mortgage services, and business financing solutions, serving local individual consumers and small to medium-sized enterprises.
TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.
BLFY vs TLSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $13.2M |
| Net Profit | $-3.5M | $-9.8M |
| Gross Margin | — | 86.7% |
| Operating Margin | — | -24.8% |
| Net Margin | -27.4% | -73.9% |
| Revenue YoY | 34.2% | 59.8% |
| Net Profit YoY | -30.6% | 3.5% |
| EPS (diluted) | $-0.18 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $13.2M | ||
| Q3 25 | $12.6M | $11.6M | ||
| Q2 25 | $12.0M | $11.2M | ||
| Q1 25 | $11.1M | $9.2M | ||
| Q4 24 | $9.9M | $8.3M | ||
| Q3 24 | $9.5M | $7.3M | ||
| Q2 24 | $10.1M | $7.4M | ||
| Q1 24 | $9.9M | $6.5M |
| Q4 25 | $-3.5M | $-9.8M | ||
| Q3 25 | $-1.9M | $-10.8M | ||
| Q2 25 | $-2.0M | $-8.3M | ||
| Q1 25 | $-2.7M | $-10.4M | ||
| Q4 24 | $-2.7M | $-10.1M | ||
| Q3 24 | $-4.0M | $-2.4M | ||
| Q2 24 | $-2.3M | $-4.3M | ||
| Q1 24 | $-2.8M | $-13.2M |
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 83.5% | ||
| Q2 25 | — | 83.9% | ||
| Q1 25 | — | 83.7% | ||
| Q4 24 | — | 85.3% | ||
| Q3 24 | — | 86.3% | ||
| Q2 24 | — | 87.6% | ||
| Q1 24 | — | 85.0% |
| Q4 25 | — | -24.8% | ||
| Q3 25 | — | -77.9% | ||
| Q2 25 | — | -65.4% | ||
| Q1 25 | — | -79.9% | ||
| Q4 24 | — | -91.8% | ||
| Q3 24 | — | -118.9% | ||
| Q2 24 | — | -111.0% | ||
| Q1 24 | — | -180.8% |
| Q4 25 | -27.4% | -73.9% | ||
| Q3 25 | -14.8% | -93.5% | ||
| Q2 25 | -16.2% | -73.9% | ||
| Q1 25 | -24.2% | -113.2% | ||
| Q4 24 | -28.4% | -122.4% | ||
| Q3 24 | -42.7% | -32.6% | ||
| Q2 24 | -23.2% | -58.8% | ||
| Q1 24 | -28.8% | -204.5% |
| Q4 25 | $-0.18 | $-0.22 | ||
| Q3 25 | $-0.10 | $-0.96 | ||
| Q2 25 | $-0.10 | $-0.27 | ||
| Q1 25 | $-0.13 | $-0.39 | ||
| Q4 24 | $-0.12 | $-0.38 | ||
| Q3 24 | $-0.19 | $-0.12 | ||
| Q2 24 | $-0.11 | $-0.21 | ||
| Q1 24 | $-0.13 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.1M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $312.7M | $-33.9M |
| Total Assets | $2.2B | $35.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.1M | $20.4M | ||
| Q3 25 | $44.1M | $22.7M | ||
| Q2 25 | $41.9M | $26.5M | ||
| Q1 25 | $46.2M | $13.0M | ||
| Q4 24 | $42.5M | $8.5M | ||
| Q3 24 | $76.1M | $11.3M | ||
| Q2 24 | $60.3M | $16.5M | ||
| Q1 24 | $53.8M | $4.0M |
| Q4 25 | $312.7M | $-33.9M | ||
| Q3 25 | $314.4M | $-26.7M | ||
| Q2 25 | $321.3M | $-19.4M | ||
| Q1 25 | $326.7M | $-34.4M | ||
| Q4 24 | $332.2M | $-25.9M | ||
| Q3 24 | $339.3M | $-20.4M | ||
| Q2 24 | $345.6M | $-25.3M | ||
| Q1 24 | $350.2M | $-36.0M |
| Q4 25 | $2.2B | $35.3M | ||
| Q3 25 | $2.2B | $36.5M | ||
| Q2 25 | $2.1B | $41.3M | ||
| Q1 25 | $2.1B | $28.6M | ||
| Q4 24 | $2.1B | $24.0M | ||
| Q3 24 | $2.1B | $27.5M | ||
| Q2 24 | $2.0B | $32.4M | ||
| Q1 24 | $2.0B | $17.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.0M | $-2.5M |
| Free Cash FlowOCF − Capex | — | $-2.5M |
| FCF MarginFCF / Revenue | — | -19.1% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-19.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.0M | $-2.5M | ||
| Q3 25 | $-255.0K | $-3.7M | ||
| Q2 25 | $2.0M | $-7.3M | ||
| Q1 25 | $-3.8M | $-4.5M | ||
| Q4 24 | $5.1M | $-5.7M | ||
| Q3 24 | $-3.7M | $-10.8M | ||
| Q2 24 | $14.1M | $-13.4M | ||
| Q1 24 | $-4.9M | $-10.9M |
| Q4 25 | — | $-2.5M | ||
| Q3 25 | — | $-3.9M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-5.3M | ||
| Q4 24 | $4.9M | $-5.8M | ||
| Q3 24 | — | $-11.0M | ||
| Q2 24 | — | $-13.5M | ||
| Q1 24 | $-4.9M | $-10.9M |
| Q4 25 | — | -19.1% | ||
| Q3 25 | — | -33.9% | ||
| Q2 25 | — | -66.1% | ||
| Q1 25 | — | -57.3% | ||
| Q4 24 | 49.8% | -69.7% | ||
| Q3 24 | — | -149.9% | ||
| Q2 24 | — | -183.1% | ||
| Q1 24 | -49.3% | -169.3% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | 1.4% | 0.6% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | 0.1% | 1.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
